US pharmaceutical giant Pfizer could make a hostile bid for AstraZeneca as early as today.
Its £63 billion takeover offer was rejected after the UK company said it "substantially" undervalued the business.
That has forced Pfizer to consider its next move, with industry experts believing a hostile bid - which would aim to bypass the AstraZeneca management and target shareholders directly - could come soon.
Last week, Pfizer insisted it was committed to building a research and development hub in Cambridge which was planned by AstraZeneca.
The £300m base at the Cambridge Biomedial Campus would house about 2,000 researchers.
But a hostile bid would trigger increased calls for the offer to be referred to the competition authorities and would also heighten union fears over jobs if the takeover was successful.
More top news
Anger is mounting over a new warehousing development in Northamptonshire - being built on top of a 4,000 year old prehistoric monument.
Sunday's marathon was the hottest on record, with temperatures reaching 23.2C.
After some sunshine this evening, it will become cloudy overnight with outbreaks of rain moving east across the region for a time.